Spyre Therapeutics Raises $400M as SPY072 Fails in PsA, AxSpA

Spyre Therapeutics said on 3 November 2026 that its third-quarter net loss widened to $96.1 million from $11.2 million a year earlier, even as the company reported positive topline induction data for SPY003 in the Phase 2 SKYLINE trial and disclosed that SPY072 missed its primary endpoints in the psoriatic arthritis and axial spondyloarthritis sub-studies of the SKYWAY basket trial. Spyre also said it raised more than $400 million in gross proceeds from an October underwritten public offering, lifting pro forma cash, cash equivalents and marketable securities to $1.47 billion as of 30 September 2026.

Context — why this matters now

The quarter crystallises a strategic pivot the company has been building toward since it began disclosing SKYLINE data in April 2026. Spyre said SPY003's positive induction readout completes proof-of-concept for all three of its monotherapies in inflammatory bowel disease, following earlier positive data for SPY001 in April and SPY002 in June.

Against that, the rheumatic disease programme has now been shut down. Spyre said SPY072 was well-tolerated in the RA sub-study and showed statistically significant benefits on one or more of the change from baseline in DAS28-CRP, ACR20 and ACR50 endpoints, but the magnitude of benefit did not meet the company's internal bar to prioritise advancement in RA. The PsA and axSpA sub-studies missed their primary endpoints of ACR20 response and change from baseline in ASDAS respectively.

The company does not plan to advance SPY072 in rheumatic diseases. That decision reallocates attention to dermatology, where Spyre said it initiated a new Phase 2 trial called SKYLIGHT in hidradenitis suppurativa, testing SPY072 in patients initiating bimekizumab as a surrogate proof-of-concept for the internal SPY772 combination of SPY072 and SPY007.

The financing followed. Spyre said the October offering and $18.0 million of October at-the-market sales together support a runway into the second half of 2029, funding a pivotal programme in HS with SPY072 as a potential best-in-class TL1A monotherapy.

Data — what the numbers show

The cash picture changed materially in the quarter. Spyre reported $1,071.9 million of cash, cash equivalents and marketable securities as of 30 September 2026, before the October raise. Pro forma for $378.0 million of net offering proceeds and $18.0 million of ATM sales, that figure rises to $1,467.9 million.

Operating burn accelerated. Net cash used in operating activities was $77.5 million for the third quarter of 2026. Research and development expenses totalled $89.2 million, up from $45.2 million in the third quarter of 2025, which the company attributed primarily to higher manufacturing costs and clinical trial expenses. General and administrative expenses rose to $16.6 million from $11.6 million, driven by increased headcount and professional services fees.

Other income fell to $9.6 million from $45.7 million a year earlier, a change Spyre linked primarily to the prior-period fair value movement in its contingent value right liability. The CVR liability sat at zero current and $6.760 million non-current on the balance sheet at 30 September 2026, versus $22.820 million current and $3.860 million non-current at 31 December 2025.

Metric	Q3 2025	Q3 2026
R&D expense	$45.2M	$89.2M
G&A expense	$11.6M	$16.6M
Net loss	$11.2M	$96.1M

The company did not disclose pricing terms or share counts for the October offering in the report.

Analysis — what it means for markets / sectors / tickers

The read-through for immunology investors is a narrowing of the TL1A thesis. Spyre said it believes TL1A has emerged as one of the most promising targets in IBD and broader immunology indications, and the RA data at least confirmed clinical activity consistent with the class. But the PsA and axSpA misses mean the company's own pipeline now concentrates that bet in IBD and HS.

For a clinical-stage issuer like Spyre, the $1.47 billion pro forma cash position is the operative number. It covers a pivotal HS programme, the SKYLINE combination readout expected in the third quarter of 2027, and the SKYLIGHT Week 16 data planned for late 2027 or early 2028, without an obvious near-term financing need. That reduces dilution risk as an overhang, but it does not offset the execution risk on the combination data, which is now the central value driver.

The clearest limitation is that SKYLIGHT is a surrogate study. Spyre is testing SPY072 in patients initiating bimekizumab, not the SPY772 combination itself, so a positive result would support rather than prove the combination thesis. The company acknowledged this framing in describing the trial.

Positioning is likely to split. Investors who bought the rheumatic disease optionality have lost that leg, while those focused on IBD combinations gained visibility with the accelerated SKYLINE Part B enrolment and the increased enrolment target. The company said the study is enrolling ahead of schedule.

Outlook — what to watch next

Three dates anchor the next twelve months. Spyre said topline induction results for the three combinations in SKYLINE Part B are expected in the third quarter of 2027, now with an increased enrolment target. SKYLIGHT topline Week 16 results are planned for late 2027 or early 2028. The company also said it plans to advance a potential best-in-class anti-TL1A monotherapy into pivotal studies for HS in 2027.

The balance sheet is the level to watch. With a runway the company expects to extend into the second half of 2029, the key question is whether R&D spending at the current $89.2 million quarterly pace stays within that guidance. Spyre gave no updated expense forecast in the report.

Frequently Asked Questions

Why did Spyre Therapeutics stock react to the SPY072 results?

The company said SPY072 was well-tolerated in the SKYWAY RA sub-study and showed statistically significant benefits on several endpoints, but the magnitude of benefit did not clear its internal bar to prioritise advancement. In PsA and axSpA, the sub-studies missed their primary endpoints. Spyre stated it does not plan to advance SPY072 in rheumatic diseases, removing a development path investors had been tracking.

What does the $400 million raise mean for Spyre's runway?

Spyre reported $1,071.9 million of cash, cash equivalents and marketable securities at 30 September 2026. Pro forma for $378.0 million of net proceeds from the October offering and $18.0 million of October ATM sales, that becomes $1,467.9 million, which the company said supports a runway into the second half of 2029. The raise funds a pivotal HS programme for SPY072.

What happens next for Spyre's hidradenitis suppurativa programme?

Spyre initiated the Phase 2 SKYLIGHT trial in September 2026, testing SPY072 in patients starting bimekizumab as a surrogate for the SPY772 combination of SPY072 and SPY007. Topline Week 16 results are planned for late 2027 or early 2028. The company also plans to advance an anti-TL1A monotherapy into pivotal HS studies in 2027.

Bottom Line

Spyre traded rheumatic disease optionality for a $1.47 billion-funded IBD and HS combination bet.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.